TISSUE PRODUCTS AND KITS FROM RENAL DISEASE

肾病组织产品和试剂盒

• 批准号: 6793501
• 负责人: VERONIQUE L BARNES
• 金额: $ 10万
• 依托单位: PROBETEX, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-05-14 至 2005-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6793501
• 关键词: CD antigens; RNase protection assay; antibody; autoantigens; basement membrane; chronic renal failure; disease /disorder model; electron microscopy; glomerulonephritis; immunocytochemistry; in situ hybridization; interstitial nephritis; laboratory rat; membranous glomerulonephritis; renal glomerulus; technology /technique development; tissue resource /registry

DESCRIPTION (provided by applicant): Kidney failure due to end-stage renal disease is escalating at an alarming rate, motivating renal investigators and clinicians to identify research priorities and impediments in the search for better ways to prevent and treat renal disease. There is a crucial need for increases in resources and manpower in research in kidney disease. An impediment to renal research has been dwindling resources and loss of protected time to devote to their research in the face of an ever-increasing demand for further exploration of research ideas. There is a significant need and market potential for readily available reagents and tissue products from established models and human cases of renal disease. To address this deficit, Probetex was founded as a "Renal Research Resource Company" to create a repository of" off-the-shelf' tissue products from renal disease to provide readily available samples and help investigators to quickly and efficiently explore their research ideas on established and standardized models or identified cases of human renal disease. This Phase I application focuses on a line of sheep antibodies produced by Probetex that induce three classical immune models of human renal disease in the rat that have been widely used by the research community and represent salient pathological features observed in human renal disease: Mesangial Proliferative Glomeruonephritis (anti-Thy-1), Immune-mediated Crescentic Glomernlonephritis and Interstitial Nephritis (anti-GBM), and Membranous Nephropathy (anti-FxlA). This grant allows the company to verify the histopathological characteristics of each model and to produce and validate tissue products (tissue sections, protein lysates, purified RNA, and prefabricated Western and Northern blots) for potential commercialization. Probetex will develop a strategy for the manufacture of multiple tissue arrays of these products for comparison analysis of samples of different diseases in the same application. As part of the long-range goal, a plan for Phase II will be developed to expand the scope of products available in the repository by large-scale development, tissue procurement and out-sourcing strategies.

描述（由申请人提供）：终末期肾病导致的肾衰竭正在以惊人的速度升级，这促使肾脏研究人员和临床医生确定研究重点和障碍，以寻找更好的方法来预防和治疗肾病。肾脏疾病研究迫切需要增加资源和人力。面对对进一步探索研究思路的需求不断增加，肾脏研究的一个障碍是资源不断减少，并且失去了投入研究的受保护时间。对来自已建立的肾病模型和人类病例的现成试剂和组织产品存在巨大的需求和市场潜力。为了解决这一缺陷，Probetex 成立为一家“肾脏研究资源公司”，旨在创建一个来自肾脏疾病的“现成”组织产品存储库，以提供现成的样本，并帮助研究人员快速有效地探索他们对已建立的标准化模型或已识别的人类肾脏疾病病例的研究思路。这一阶段的应用重点关注 Probetex 生产的一系列绵羊抗体，这些抗体可诱导人类肾脏疾病的三种经典免疫模型。 大鼠已被研究界广泛使用，代表了人类肾脏疾病中观察到的显着病理特征：系膜增生性肾小球肾炎（抗 Thy-1）、免疫介导的新月体肾小球肾炎和间质性肾炎（抗 GBM）和膜性肾病（抗 FxlA）。这笔赠款使公司能够验证组织病理学 每种模型的特征，并生产和验证组织产品（组织切片、蛋白质裂解物、纯化的 RNA 以及预制的 Western 和 Northern 印迹）以实现潜在的商业化。 Probetex 将制定一种策略，用于制造这些产品的多个组织阵列，以便在同一应用中对不同疾病的样本进行比较分析。作为长期目标的一部分，将制定第二阶段计划，通过以下方式扩大存储库中可用产品的范围： 大规模开发、组织采购和外包策略。